A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers — Stella

Home/Thromboangiitis Obliterans (Buerger's Disease)/

View on ClinicalTrials.gov

Recruiting

Back to Thromboangiitis Obliterans (Buerger's Disease) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Dr. Vince Clinical Research, Overland Park, Kansas

Key details

Phase

Early testing

Sponsor

Antidote Therapeutics, Inc

Collaborators

National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

Enrollment target

~15 participants

Started

October 2025

Primary completion

June 2026

Age range

23 Years – 59 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.